Literature DB >> 17412618

Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania.

Beatriz León1, María López-Bravo, Carlos Ardavín.   

Abstract

Infection-induced inflammatory reactions involve a strong increase in dendritic cells (DCs) at the infection site and draining lymph nodes (dLNs). Whether inflammatory DCs are recruited to these locations or differentiate locally, and what their functional relevance is, remain unclear. Here we showed that during Leishmania infection, monocytes were recruited to the dermis and differentiated into "dermal monocyte-derived DCs," which subsequently migrated into the dLNs. In addition, monocyte recruitment to the dLNs resulted in the differentiation into "LN monocyte-derived DCs." Analysis of the kinetics of monocyte differentiation into DCs, susceptibility to infection, IL-12 production, and L. major-specific T cell stimulation potential suggest that dermal monocyte-derived DCs controlled the induction of protective T helper 1 responses against Leishmania. Thus, the demonstration of monocyte differentiation potential into DCs during in vivo infection and of local DC differentiation in inflammatory foci suggests that de novo formed monocyte-derived DCs are essential in T cell immunity against pathogens.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17412618     DOI: 10.1016/j.immuni.2007.01.017

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  298 in total

Review 1.  Transcriptional programming of the dendritic cell network.

Authors:  Gabrielle T Belz; Stephen L Nutt
Journal:  Nat Rev Immunol       Date:  2012-01-25       Impact factor: 53.106

Review 2.  Functional regulation of monocyte-derived dendritic cells by microRNAs.

Authors:  Yifan Zhan; Li Wu
Journal:  Protein Cell       Date:  2012-07-10       Impact factor: 14.870

3.  Identification of an important immunological difference between virulent varicella-zoster virus and its avirulent vaccine: viral disruption of dendritic cell instruction.

Authors:  Cindy Gutzeit; Martin J Raftery; Matthias Peiser; Karsten B Tischer; Martina Ulrich; Melanie Eberhardt; Eggert Stockfleth; Thomas Giese; Andreas Sauerbrei; Craig T Morita; Günther Schönrich
Journal:  J Immunol       Date:  2010-06-04       Impact factor: 5.422

4.  Nitric oxide controls an inflammatory-like Ly6C(hi)PDCA1+ DC subset that regulates Th1 immune responses.

Authors:  Daniela Giordano; Chang Li; Mehul S Suthar; Kevin E Draves; Daphne Y Ma; Michael Gale; Edward A Clark
Journal:  J Leukoc Biol       Date:  2010-12-22       Impact factor: 4.962

5.  Targeted tumor necrosis factor receptor I preligand assembly domain improves skin lesions in MRL/lpr mice.

Authors:  Guo-Min Deng; Lena Liu; George C Tsokos
Journal:  Arthritis Rheum       Date:  2010-08

6.  Flt3 Ligand Is Essential for Survival and Protective Immune Responses during Toxoplasmosis.

Authors:  Christopher D Dupont; Gretchen Harms Pritchard; Shinya Hidano; David A Christian; Sagie Wagage; Gaia Muallem; Elia D Tait Wojno; Christopher A Hunter
Journal:  J Immunol       Date:  2015-09-18       Impact factor: 5.422

7.  Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cells.

Authors:  Michael Y Gerner; Matthew F Mescher
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

8.  Complement receptor C5aR1/CD88 and dipeptidyl peptidase-4/CD26 define distinct hematopoietic lineages of dendritic cells.

Authors:  Hideki Nakano; Timothy P Moran; Keiko Nakano; Kevin E Gerrish; Carl D Bortner; Donald N Cook
Journal:  J Immunol       Date:  2015-03-13       Impact factor: 5.422

Review 9.  HIV infection of the genital mucosa in women.

Authors:  Florian Hladik; Thomas J Hope
Journal:  Curr HIV/AIDS Rep       Date:  2009-02       Impact factor: 5.071

10.  Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses.

Authors:  Michael Y Gerner; Kerry A Casey; Matthew F Mescher
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.